Matthew R. Henn - Apr 27, 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role: Chief Scientific Officer and EVP
Signature: /s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn
Stock symbol: MCRB
Transactions as of: Apr 27, 2023
Transactions value $: $0
Form type: 4
Date filed: 5/1/2023, 04:41 PM
Previous filing: Feb 7, 2023
Next filing: Oct 31, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MCRB	Stock Option (Right to Buy)	Award	$0	+35K	+100%	$0.00	70K	Apr 27, 2023	Common Stock	35K	$10.84	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. The option vested and became exercisable in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in vesting of the option as to 35,000 shares.

Content

On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. The option vested and became exercisable in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in vesting of the option as to 35,000 shares.

Remarks:

Chief Scientific Officer and EVP